MX2007011976A - Composiciones farmaceuticas novedosas utiles en el tratamiento de la enfermedad de parkinson. - Google Patents

Composiciones farmaceuticas novedosas utiles en el tratamiento de la enfermedad de parkinson.

Info

Publication number
MX2007011976A
MX2007011976A MX2007011976A MX2007011976A MX2007011976A MX 2007011976 A MX2007011976 A MX 2007011976A MX 2007011976 A MX2007011976 A MX 2007011976A MX 2007011976 A MX2007011976 A MX 2007011976A MX 2007011976 A MX2007011976 A MX 2007011976A
Authority
MX
Mexico
Prior art keywords
further characterized
composition according
particles
composition
acid
Prior art date
Application number
MX2007011976A
Other languages
English (en)
Spanish (es)
Inventor
Anders Pettersson
Thomas Lundqvist
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of MX2007011976A publication Critical patent/MX2007011976A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2007011976A 2005-03-28 2006-03-28 Composiciones farmaceuticas novedosas utiles en el tratamiento de la enfermedad de parkinson. MX2007011976A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66537605P 2005-03-28 2005-03-28
PCT/GB2006/001132 WO2006103417A1 (en) 2005-03-28 2006-03-28 New pharmaceutical compositions useful in the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
MX2007011976A true MX2007011976A (es) 2007-12-07

Family

ID=34956744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011976A MX2007011976A (es) 2005-03-28 2006-03-28 Composiciones farmaceuticas novedosas utiles en el tratamiento de la enfermedad de parkinson.

Country Status (13)

Country Link
US (1) US20080193526A1 (OSRAM)
EP (1) EP1863455A1 (OSRAM)
JP (1) JP2008534563A (OSRAM)
KR (1) KR20070114734A (OSRAM)
CN (1) CN101141949B (OSRAM)
AU (1) AU2006228296B2 (OSRAM)
CA (1) CA2599384A1 (OSRAM)
IL (1) IL185300A0 (OSRAM)
MX (1) MX2007011976A (OSRAM)
NO (1) NO20074199L (OSRAM)
NZ (1) NZ560826A (OSRAM)
RU (1) RU2440100C2 (OSRAM)
WO (1) WO2006103417A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
AR055106A1 (es) * 2005-08-05 2007-08-08 Osmotica Pharmaceutical Argent Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
AU2008343787B2 (en) * 2007-12-28 2014-01-30 Impax Laboratories, Llc Controlled release formulations of levodopa and uses thereof
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
WO2014186410A1 (en) 2013-05-13 2014-11-20 NeuOra Microceuticals, LLC Long lasting breath mint
KR101850479B1 (ko) 2015-07-22 2018-05-30 (주)듀켐바이오 [18F]플루오로-도파의 중성 pH 안정화 방법
RU2697411C2 (ru) * 2017-10-11 2019-08-14 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Композиция для лечения болезни Паркинсона

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5414167B1 (OSRAM) * 1970-12-28 1979-06-05
SE8800080L (sv) * 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
HU209564B (en) * 1991-01-30 1994-07-28 Egyt Gyogyszervegyeszeti Gyar Process for producing rapide tablets containing levodopa and carbidopa
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6531153B2 (en) * 2001-05-29 2003-03-11 Drugtech Corporation Composition with sustained release of levodopa and carbidopa
CA2512559A1 (en) * 2003-01-31 2004-08-12 Orexo Ab A rapid-acting pharmaceutical composition
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции

Also Published As

Publication number Publication date
RU2007139826A (ru) 2009-05-10
AU2006228296B2 (en) 2011-08-04
NZ560826A (en) 2009-06-26
US20080193526A1 (en) 2008-08-14
KR20070114734A (ko) 2007-12-04
JP2008534563A (ja) 2008-08-28
WO2006103417A1 (en) 2006-10-05
EP1863455A1 (en) 2007-12-12
IL185300A0 (en) 2008-02-09
NO20074199L (no) 2007-11-21
CA2599384A1 (en) 2006-10-05
CN101141949B (zh) 2010-12-08
AU2006228296A1 (en) 2006-10-05
CN101141949A (zh) 2008-03-12
RU2440100C2 (ru) 2012-01-20

Similar Documents

Publication Publication Date Title
US20080248110A1 (en) Pharmaceutical Compositions Useful in the Treatment of Pain
WO2003072084A1 (en) Fast disintegrating tablets
US20090232898A1 (en) Pharmaceutical Compositions Useful in the Treatment of Migraine
JP2001058944A (ja) 速崩壊性固形製剤
WO2010038691A1 (ja) 経口投与用粒子状医薬組成物
US20120277261A1 (en) Pharmaceutical formulations useful in the treatment of insomnia
US20050175689A1 (en) Coated fine particles containing drug for intrabuccally fast disintegrating tablet
AU2006228296B2 (en) New pharmaceutical compositions useful in the treatment of Parkinson's disease
CN104427978B (zh) 用于治疗急性疼痛的阿芬太尼组合物
EP1679066A1 (en) Drug-containing coated microparticle for orally disintegrating tablet
JP2006070046A (ja) 速崩壊性固形製剤
CA2893480A1 (en) Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
ES2642213T3 (es) Nuevas formulaciones farmacéuticas útiles en el tratamiento del insomnio
TW201729798A (zh) 口腔內保持型崩解性固形製劑、其製造方法、及用於該製造方法之粉體組成物